readthroughSign in
Oct 9, 2026PeopleUpdated

Quince Therapeutics becomes IRulya Therapeutics, names new CEO, moves to Nasdaq ticker IRLA

The company completed its name change October 9, 2026, installed Brigette Roberts as CEO, and said its $116 million cash balance should fund operations into late 2028.

Quince Therapeutics, Inc. announced it had changed its name to IRulya Therapeutics Inc., effective at 4:01 p.m. Eastern Time on October 9, 2026. IRulya will focus on advancing LAM-001, an investigational formulation of inhaled rapamycin, an mTOR inhibitor, for multiple pulmonary diseases.1 The name change follows completion of a previously announced merger with privately held Orphai Therapeutics and a concurrent private placement that raised roughly $115 million in upfront gross proceeds in May 2026.1 Common stock will trade on the Nasdaq Capital Market under the new symbol "IRLA" starting October 12, 2026, moving from the Nasdaq Global Select Market.

The company reported a cash balance of $116 million as of June 30, 2026, which it expects to fund operations through the end of 2028, supporting anticipated clinical data readouts from Phase 2 studies of LAM-001 in bronchiolitis obliterans syndrome (BOS), pulmonary hypertension associated with interstitial lung disease (PH-ILD), and sarcoidosis-associated pulmonary hypertension (SAPH).1

Brigette Roberts, M.D., was appointed Chief Executive Officer effective October 8, 2026, succeeding Dirk Thye, who resigned as CEO, Chief Medical Officer and director. Brendan Hannah, the company's Chief Operating Officer, Chief Business Officer and Chief Compliance Officer, also resigned.1 John Militello was named Chief Financial Officer and Keith R. Fandrick Chief Operating Officer. Directors June Bray, David Lamond, Christopher Senner and Thye resigned from the board effective October 8, 2026, in moves the filing said were not the result of any disagreement with the company.1 Catherine Bonuccelli, Leone Patterson, James Valentine and Drayton Wise joined the board the same day.

On October 6, 2026, stockholders approved conversion of the company's Series C preferred stock and related warrants tied to the May 2026 Orphai acquisition, triggering automatic conversion effective 5:00 p.m. Eastern Time on October 9, 2026, which the company expects will bring outstanding common stock to approximately 10,841,470 shares.1 The company also relocated its principal executive office to New Haven, Connecticut, effective October 10, 2026.1

Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.